American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the ...
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based ...
Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...
The ideal indication for NSS in the presence of a normal contralateral kidney is, therefore, the presence of an easily resectable, small (4 cm diameter or less), solitary, exophytic renal tumor ...
A highly vascularized cancer that is especially reliant on tumor endothelial cells is clear cell renal cell carcinoma (ccRCC). Almost 80% of malignant tumors in the kidney are ccRCC ... She found that ...
All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.
Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...
Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear cell RCC with or without ipilimumab.
The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback